已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

蛋白尿 医学 肾脏疾病 肌酐 内科学 队列研究 肾功能 队列
作者
Josef Coresh,Hiddo J.L. Heerspink,Yingying Sang,Kunihiro Matsushita,Johan Ärnlöv,Brad C. Astor,Corri Black,Nigel J. Brunskill,Juan Jesús Carrero,Harold I. Feldman,Caroline S. Fox,Lesley A. Inker,Areef Ishani,Sadayoshi Ito,Simerjot K Jassal,Tsuneo Konta,Kevan R. Polkinghorne,Solfrid Romundstad,Marit D. Solbu,Nikita Stempniewicz
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:7 (2): 115-127 被引量:319
标识
DOI:10.1016/s2213-8587(18)30313-9
摘要

Background Change in albuminuria as a surrogate endpoint for progression of chronic kidney disease is strongly supported by biological plausibility, but empirical evidence to support its validity in epidemiological studies is lacking. We aimed to assess the consistency of the association between change in albuminuria and risk of end-stage kidney disease in a large individual participant-level meta-analysis of observational studies. Methods In this meta-analysis, we collected individual-level data from eligible cohorts in the Chronic Kidney Disease Prognosis Consortium (CKD-PC) with data on serum creatinine and change in albuminuria and more than 50 events on outcomes of interest. Cohort data were eligible if participants were aged 18 years or older, they had a repeated measure of albuminuria during an elapsed period of 8 months to 4 years, subsequent end-stage kidney disease or mortality follow-up data, and the cohort was active during this consortium phase. We extracted participant-level data and quantified percentage change in albuminuria, measured as change in urine albumin-to-creatinine ratio (ACR) or urine protein-to-creatinine ratio (PCR), during baseline periods of 1, 2, and 3 years. Our primary outcome of interest was development of end-stage kidney disease after a baseline period of 2 years. We defined an end-stage kidney disease event as initiation of kidney replacement therapy. We quantified associations of percentage change in albuminuria with subsequent end-stage kidney disease using Cox regression in each cohort, followed by random-effects meta-analysis. We further adjusted for regression dilution to account for imprecision in the estimation of albuminuria at the participant level. We did multiple subgroup analyses, and also repeated our analyses using participant-level data from 14 clinical trials, including nine clinical trials not in CKD-PC. Findings Between July, 2015, and June, 2018, we transferred and analysed data from 28 cohorts in the CKD-PC, which included 693 816 individuals (557 583 [80%] with diabetes). Data for 675 904 individuals and 7461 end-stage kidney disease events were available for our primary outcome analysis. Change in ACR was consistently associated with subsequent risk of end-stage kidney disease. The adjusted hazard ratio (HR) for end-stage kidney disease after a 30% decrease in ACR during a baseline period of 2 years was 0·83 (95% CI 0·74–0·94), decreasing to 0·78 (0·66–0·92) after further adjustment for regression dilution. Adjusted HRs were fairly consistent across cohorts and subgroups (ie, estimated glomerular filtration rate, diabetes, and sex), but the association was somewhat stronger among participants with higher baseline ACR than among those with lower baseline ACR (pinteraction<0·0001). In individuals with baseline ACR of 300 mg/g or higher, a 30% decrease in ACR over 2 years was estimated to confer a more than 1% absolute reduction in 10-year risk of end-stage kidney disease, even at early stages of chronic kidney disease. Results were generally similar when we used change in PCR and when study populations from clinical trials were assessed. Interpretation Change in albuminuria was consistently associated with subsequent risk of end-stage kidney disease across a range of cohorts, lending support to the use of change in albuminuria as a surrogate endpoint for end-stage kidney disease in clinical trials of progression of chronic kidney disease in the setting of increased albuminuria. Funding US National Kidney Foundation and US National Institute of Diabetes and Digestive and Kidney Diseases.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wesley完成签到 ,获得积分10
1秒前
王化省完成签到,获得积分10
4秒前
彭于晏的应助被气球好饿采纳,获得10
5秒前
9秒前
Milton_z完成签到 ,获得积分0
10秒前
学霸业的应助被DW采纳,获得10
10秒前
华仔的应助被微山采纳,获得10
10秒前
11秒前
12秒前
cjg完成签到 ,获得积分10
13秒前
Rebirth发布了新的文献求助10
13秒前
meow完成签到 ,获得积分10
14秒前
机智的如曼完成签到,获得积分10
14秒前
哦哦哟完成签到 ,获得积分10
14秒前
Lw完成签到,获得积分10
16秒前
汪汪完成签到 ,获得积分10
16秒前
跳不起来的大神完成签到 ,获得积分10
17秒前
花落雨凇的应助被邢绿凝采纳,获得10
17秒前
可爱的函函的应助被Gari采纳,获得10
18秒前
zzz完成签到 ,获得积分10
19秒前
Dao完成签到 ,获得积分10
20秒前
七七完成签到 ,获得积分10
20秒前
瑩火虫完成签到 ,获得积分10
20秒前
mingming完成签到 ,获得积分10
22秒前
molihuakai的应助被石永怡采纳,获得10
22秒前
学霸业的应助被DW采纳,获得10
23秒前
背后的尔琴完成签到 ,获得积分10
23秒前
alvinw完成签到,获得积分10
24秒前
24秒前
芒果完成签到 ,获得积分10
25秒前
xzp完成签到,获得积分10
26秒前
知北游完成签到 ,获得积分10
26秒前
cen关闭了cen的文献求助
28秒前
深情安青的应助被邢绿凝采纳,获得10
29秒前
30秒前
Lan完成签到 ,获得积分10
31秒前
31秒前
32秒前
糖豆完成签到,获得积分10
32秒前
光亮的小甜瓜完成签到 ,获得积分10
34秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184764
求助须知:如何正确求助?哪些是违规求助? 9573733
关于积分的说明 21832921
捐赠科研通 7782115
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481067